Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal Cancer

Preoperative chemoradiotherapy (CRT) is a standard treatment for locally advanced rectal cancer (RC) patients, but its use in non-responders can be associated with increased toxicities and resection delay. LincRNA-p21 is a long non-coding RNA involved in the p53 pathway and angiogenesis regulation....

ver descrição completa

Detalhes bibliográficos
Autores: Benítez Montañez, José Carlos, Campayo Guillaumes, Marc, Díaz Sánchez, Tania, Ferrer, Carme, Acosta Plasencia, Melissa, Monzó Planella, Mariano, Cirera, Lluís, Besse, Benjamin, Navarro Ponz, Alfons
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Recursos:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/180124
Acesso em linha:https://hdl.handle.net/2445/180124
Access Level:acceso abierto
Palavra-chave:Càncer colorectal
Quimioteràpia del càncer
Colorectal cancer
Cancer chemotherapy
id ES_80e511cdd65eb1312f28a36b5148ee8b
oai_identifier_str oai:diposit.ub.edu:2445/180124
network_acronym_str ES
network_name_str España
repository_id_str
spelling Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal CancerBenítez Montañez, José CarlosCampayo Guillaumes, MarcDíaz Sánchez, TaniaFerrer, CarmeAcosta Plasencia, MelissaMonzó Planella, MarianoCirera, LluísBesse, BenjaminNavarro Ponz, AlfonsCàncer colorectalQuimioteràpia del càncerColorectal cancerCancer chemotherapyPreoperative chemoradiotherapy (CRT) is a standard treatment for locally advanced rectal cancer (RC) patients, but its use in non-responders can be associated with increased toxicities and resection delay. LincRNA-p21 is a long non-coding RNA involved in the p53 pathway and angiogenesis regulation. We aimed to study whether lincRNA-p21 expression levels can act as a predictive biomarker for neoadjuvant CRT response. We analyzed RNAs from pretreatment biopsies from 70 RC patients treated with preoperative CRT. Pathological response was classified according to the tumor regression grade (TRG) Dworak classification. LincRNA-p21 expression was determined by RTqPCR. The results showed that lincRNA-p21 was upregulated in stage III tumors (p = 0.007) and in tumors with the worst response regarding TRG (p = 0.027) and downstaging (p = 0.016). ROC curve analysis showed that lincRNA-p21 expression had the capacity to distinguish a complete response from others (AUC:0.696; p = 0.014). LincRNA-p21 was shown as an independent marker of preoperative CRT response (p = 0.047) and for time to relapse (TTR) (p = 0.048). In conclusion, lincRNA-p21 is a marker of advanced disease, worse response to neoadjuvant CRT, and shorter TTR in locally advanced RC patients. The study of lincRNA-p21 may be of value in the individualization of pre-operative CRT in RC.MDPI2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/180124Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.3390/jpm11050420Journal of Personalized Medicine, 2021, vol. 11, num. 420https://doi.org/10.3390/jpm11050420cc-by (c) Benitez, Jose Carlos et al., 2021https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1801242026-05-27T06:46:51Z
dc.title.none.fl_str_mv Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal Cancer
title Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal Cancer
spellingShingle Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal Cancer
Benítez Montañez, José Carlos
Càncer colorectal
Quimioteràpia del càncer
Colorectal cancer
Cancer chemotherapy
title_short Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal Cancer
title_full Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal Cancer
title_fullStr Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal Cancer
title_full_unstemmed Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal Cancer
title_sort Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal Cancer
dc.creator.none.fl_str_mv Benítez Montañez, José Carlos
Campayo Guillaumes, Marc
Díaz Sánchez, Tania
Ferrer, Carme
Acosta Plasencia, Melissa
Monzó Planella, Mariano
Cirera, Lluís
Besse, Benjamin
Navarro Ponz, Alfons
author Benítez Montañez, José Carlos
author_facet Benítez Montañez, José Carlos
Campayo Guillaumes, Marc
Díaz Sánchez, Tania
Ferrer, Carme
Acosta Plasencia, Melissa
Monzó Planella, Mariano
Cirera, Lluís
Besse, Benjamin
Navarro Ponz, Alfons
author_role author
author2 Campayo Guillaumes, Marc
Díaz Sánchez, Tania
Ferrer, Carme
Acosta Plasencia, Melissa
Monzó Planella, Mariano
Cirera, Lluís
Besse, Benjamin
Navarro Ponz, Alfons
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Càncer colorectal
Quimioteràpia del càncer
Colorectal cancer
Cancer chemotherapy
topic Càncer colorectal
Quimioteràpia del càncer
Colorectal cancer
Cancer chemotherapy
description Preoperative chemoradiotherapy (CRT) is a standard treatment for locally advanced rectal cancer (RC) patients, but its use in non-responders can be associated with increased toxicities and resection delay. LincRNA-p21 is a long non-coding RNA involved in the p53 pathway and angiogenesis regulation. We aimed to study whether lincRNA-p21 expression levels can act as a predictive biomarker for neoadjuvant CRT response. We analyzed RNAs from pretreatment biopsies from 70 RC patients treated with preoperative CRT. Pathological response was classified according to the tumor regression grade (TRG) Dworak classification. LincRNA-p21 expression was determined by RTqPCR. The results showed that lincRNA-p21 was upregulated in stage III tumors (p = 0.007) and in tumors with the worst response regarding TRG (p = 0.027) and downstaging (p = 0.016). ROC curve analysis showed that lincRNA-p21 expression had the capacity to distinguish a complete response from others (AUC:0.696; p = 0.014). LincRNA-p21 was shown as an independent marker of preoperative CRT response (p = 0.047) and for time to relapse (TTR) (p = 0.048). In conclusion, lincRNA-p21 is a marker of advanced disease, worse response to neoadjuvant CRT, and shorter TTR in locally advanced RC patients. The study of lincRNA-p21 may be of value in the individualization of pre-operative CRT in RC.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/180124
url https://hdl.handle.net/2445/180124
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/jpm11050420
Journal of Personalized Medicine, 2021, vol. 11, num. 420
https://doi.org/10.3390/jpm11050420
dc.rights.none.fl_str_mv cc-by (c) Benitez, Jose Carlos et al., 2021
https://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Benitez, Jose Carlos et al., 2021
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411933521707008
score 15,198674

Registos relacionados